VITA, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.262
AS - Asia 1.505
EU - Europa 1.496
SA - Sud America 182
Continente sconosciuto - Info sul continente non disponibili 98
AF - Africa 39
OC - Oceania 3
AN - Antartide 1
Totale 7.586
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.088
CN - Cina 665
RU - Federazione Russa 416
SG - Singapore 409
IT - Italia 246
DE - Germania 236
BR - Brasile 153
CA - Canada 133
UA - Ucraina 116
GB - Regno Unito 113
HK - Hong Kong 105
VN - Vietnam 97
SE - Svezia 83
FR - Francia 78
FI - Finlandia 68
KR - Corea 43
IN - India 41
TR - Turchia 37
IE - Irlanda 27
CZ - Repubblica Ceca 24
JP - Giappone 24
PL - Polonia 24
ZA - Sudafrica 19
MX - Messico 18
ES - Italia 16
IL - Israele 14
BE - Belgio 13
BD - Bangladesh 12
IQ - Iraq 10
AR - Argentina 9
EU - Europa 9
IR - Iran 8
NL - Olanda 8
VE - Venezuela 7
CR - Costa Rica 6
ID - Indonesia 6
CO - Colombia 5
LT - Lituania 5
SC - Seychelles 5
AT - Austria 4
EG - Egitto 4
PR - Porto Rico 4
RO - Romania 4
UY - Uruguay 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CW - ???statistics.table.value.countryCode.CW??? 3
GT - Guatemala 3
KE - Kenya 3
MA - Marocco 3
MY - Malesia 3
NP - Nepal 3
PH - Filippine 3
PK - Pakistan 3
TW - Taiwan 3
DK - Danimarca 2
EC - Ecuador 2
HN - Honduras 2
JM - Giamaica 2
KG - Kirghizistan 2
OM - Oman 2
PT - Portogallo 2
RS - Serbia 2
TH - Thailandia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AQ - Antartide 1
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
CL - Cile 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
HR - Croazia 1
JO - Giordania 1
LB - Libano 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
NI - Nicaragua 1
NR - Nauru 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
SA - Arabia Saudita 1
SV - El Salvador 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.501
Salva come PNG Salva come JPEG
Città #
Ashburn 560
Jacksonville 289
Woodbridge 228
San Jose 213
Chandler 201
Singapore 199
Houston 183
Fairfield 168
Ann Arbor 146
Dallas 142
Boardman 123
Council Bluffs 112
Beijing 109
Hong Kong 100
Wilmington 100
Nanjing 83
Seattle 78
Toronto 78
New York 73
Los Angeles 64
The Dalles 62
Cambridge 59
San Mateo 54
Princeton 52
Ho Chi Minh City 41
Nanchang 41
Chicago 39
Washington 39
Seoul 38
Columbus 37
Lawrence 36
Tongling 36
Lauterbourg 33
Düsseldorf 32
Dearborn 30
Helsinki 29
Istanbul 29
Santa Clara 29
Ogden 27
São Paulo 27
Buffalo 26
Dublin 25
Lachine 25
Tianjin 24
Orem 21
Shanghai 21
Hanoi 20
Redwood City 20
Acquaviva 19
Hebei 19
Milan 18
Johannesburg 17
Guangzhou 16
Tokyo 16
Camerino 14
Leawood 14
London 14
Moscow 14
Shenyang 14
Brooklyn 13
Brussels 13
Kunming 13
Montreal 13
Bremen 12
Brno 12
Chennai 12
Jiaxing 12
North Bergen 12
Atlanta 11
Changsha 11
Hangzhou 11
Jinan 11
Mumbai 11
Kraków 10
Nürnberg 10
Olomouc 10
Phoenix 10
Stockholm 10
Warsaw 10
San Francisco 9
Changchun 8
Frankfurt am Main 8
Manchester 8
Mexico City 8
Rome 8
Ankara 7
Ardabil 7
Augusta 7
Denver 7
Munich 7
Queens 7
Sapporo 7
Zhengzhou 7
Indianapolis 6
Monmouth Junction 6
Rio de Janeiro 6
San José 6
Stuttgart 6
Venezia 6
Wuhan 6
Totale 4.750
Salva come PNG Salva come JPEG
Nome #
Sugar-modified nucleosides: synthesis, conformational analysis and biological evaluation 283
5'-CHLORO-5'-DEOXY-N6-(±)-endo-NORBORNYLADENOSINE, A POTENT AND HIGHLY SELECTIVE HUMAN A1 ADENOSINE RECEPTOR AGONIST, PREVENTS HYPERALGESIA/ALLODYNIA AND EARLY OVER-EXPRESSION OF PRO-APOPTOTIC AND PRO-INFLAMMATORY GENES IN A MICE MODEL OF NEUROPATHIC PAIN 270
2’-C-Methyl derivatives of tecadenoson and 2-chloro-tecadenoson with increased selectivity for human A1 adenosine receptor 265
ADP- and ATP-mimetics derived from 2'(3')-C-methyladenosine as human P2Y1 and P2Y2 receptor ligands 254
Structure-Based Design, Synthesis and in vivo Antinociceptive Effects of Selective A1 Adenosine Receptor Agonists 253
ATP-mimetics derived from 2 '(3 ')-C-methyladenosine as human P2Y2 agonists 249
5’-deoxy-5’-N-pyrazolyl-N6-substituded adenosine derivates as A1 adenosine receptor agonists: synthesis and antinociception in mice 249
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine 234
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents 230
Synthesis and Biological Evaluation of NAD Analogs as Human Pyridine Nucleotide Adenylyltransferase Inhibitors 230
Stereoselective synthesis of nicotinamide β-riboside and nucleoside analogs 230
5'-Chloro-5'-deoxy-N6-(±)-endo-norbornyladenosine, a potent and highly selective human A1 adenosine receptor agonist modulates neuropathic pain in mice. 230
Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade 226
N6/5’-DISUBSTITUTED ADENOSINE AND 2-CHLORO-ADENOSINE DERIVATIVES AS POTENT AND SELECTIVE A1 ADENOSINE RECEPTOR AGONISTS: SYNTHESIS, BINDING ASSAYS AND ANTINOCICEPTIVE ACTIVITY IN MICE 221
5’-CHLORO-5’-DEOXY-N6-SUBSTITUTED ADENOSINE DERIVATIVES: SYNTHESIS, ADENOSINE RECEPTOR AFFINITY AND ANTINOCICEPTIVE ACTIVITY 220
Purine and pyrimidine nucleoside analogs of 3'-C-methyladenosine as antitumor agents 219
Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of lamivudine and tenofovir 216
3’-C-Methyl-ribosyl nucleosides as cytotoxic compounds 211
Affinity and selectivity of tecadenoson, 2-chloro-tecadenoson and 2’-C-methyl analogues at bovine and pig A1 adenosine receptor 205
Antitumor effects of novel co-drugs linking histone deacetylase and ribonucleotide reductase inhibitors in hematological tumors 205
Synthesis and antitumor activity of a heterodinucleotide of BVDU and Gemcitabine 203
ADP-, and ATP-mimetics derived from 2'(3')-C-methyladenosine as human P2Y1 and P2Y2 ligands 200
Synthesis and biological evaluation of (methylene)bisphosphonate derivatives of 2’-C-methyl-, and 3’-C-methyl-adenosine 200
First TiCl4-Mediated Diastereoslective Reduction of alpha-Nitro Ketones to beta-Nitro Alcohols by BH3.SMe2 199
Selective inhibition of nicotinamide adenine kinases (NADKs) by compact NAD mimics 189
Bisphosphonate Derivatives of 2’-C-Methyl-, and 3’-C-Methyl-Adenosine as Ligands at P2Y1 and P2Y2 Receptors 189
Ribose-modified mizoribine analogues: synthesis and biological evaluation 188
NOVEL 2-SUBSTITUTED 2’/3’-C-METHYL-ADENOSINE DERIVATIVES: SYNTHESIS AND BIOLOGICAL EVALUATION AGAINST TRYPANOSOMA BRUCEI 188
Structure-affinity relathionships of 5'-carbamoyl- and 5'-thionocarbamoyl derivatives of the A1 selective adenosine receptor agonist 2'-MeCCPA as partial A1 agonists 182
Design, synthesis and biological evaluation of novel inhibitors of NAD kinase 182
EFFECTS OF METAL(III) COORDINATION ON BIOLOGICAL ACTIVITY OF 2,2'-BIPYRIDYL-6-CARBOTHIOAMIDE (BPYTA), A POTENT R2 RIBONUCLEOTIDE REDUCTASE INHIBITOR 179
N6/5’-DISUBSTITUTED ADENOSINE AND 2-CHLORO-ADENOSINE DERIVATIVES AS POTENT AND SELECTIVE A1 ADENOSINE RECEPTOR AGONISTS: SYNTHESIS, BINDING ASSAYS AND ANTINOCICEPTIVE ACTIVITY IN MICE 172
Synthesis and Enzymatic Evaluation of NAD Mimics as Nicotinamide Adenine Dinucleotide Kinase (NADK) Inhibitors 161
Dual-target dimeric molecules with antitumor properties. Synthesis and biological activity of 3’-C-methyladenosine-valproates 159
PROBING BINDING REQUIREMENTS OF NAD KINASE WITH MODIFIED NAD ANALOGUES 158
New N6-substituted adenosine and 3’-C-methyl-adenosine derivatives as antitumor agents 137
Totale 7.586
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.406
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022200 0 0 0 0 17 23 11 23 30 26 29 41
2022/2023546 68 15 33 71 53 77 1 41 105 27 38 17
2023/2024476 60 29 34 5 24 77 17 23 39 24 9 135
2024/20251.258 58 28 114 50 53 69 193 290 121 72 61 149
2025/20261.653 95 149 155 260 193 140 229 77 61 146 85 63
2026/2027830 88 45 176 436 85 0 0 0 0 0 0 0
Totale 7.586